Trials by Country
48 videos · last 6 months shuffled daily, then older videos newest first
▶
59:52 Earli's Cyriac Roeding on Cancer, China and Biotech Funding
Earli co-founder and CEO Cyriac Roeding discusses the company's in vivo approach to cancer, China's 2026-2030 biotech plan and how US funding cycles affect early-stage drug development, on Life Science Connect's Business of Biotech.
▶
59:30 Demystifying North American IRB EC Requirements for International Research Professionals
Advarra experts explain the US Institutional Review Board process, its regulatory requirements and submission timelines, for sponsors and CROs based outside North America.
▶
19:23 Why Cancer Patients Are Flying to China for Treatment
BBC World Service's Asia Specific examines why a growing number of cancer patients travel to China for CAR-T cell therapy that can be faster, cheaper and more accessible than in many Western countries.
▶
12:27 Why Are Clinical Trials Moving So Fast in China? - Voices of SCOPE
Gary Ma, President and CEO of Taimei Technology US, discusses what drives the speed of clinical trials in China, including streamlined processes, digital tools, CRC support for investigators and hospital networks linking patients to trials, for SCOPE 365.
▶
45:51 Country-Wide Barriers to Clinical Trial Access in Colorectal Cancer
Dr. Cecilia Monge, Medical Director in Clinical Development at Johnson & Johnson, explores barriers to colorectal cancer trial access in low- and middle-income nations, from research capacity to diverse enrollment, for the Global Colon Cancer Association.
▶
19:43 Steven Knapper on a Decade of AML Clinical Trials
Professor Steven Knapper, Chief Investigator of the Cancer Research UK-funded AML18 trial across about 90 centres in the UK and Denmark, reflects on over a decade of AML trials with Cardiff University's Centre for Trials Research.
▶
59:53 Designing Clinical Trials With Implementation Science
An Australian Clinical Trials Alliance webinar explores how embedding implementation science in clinical trials can improve study design and conduct and help effective interventions be adopted and sustained, with a case study and consumer involvement.
▶
8:59 Season 5, Episode 3: Global Regulatory Strategy: Navigating FDA, EMA, and Emerging Markets
Eric and Sarah of EMMA International on building a global regulatory strategy across the FDA, the European Medicines Agency and emerging health authorities.
▶
28:30 Vistatec Life Sciences - In Focus Podcast Ep 28 - Sara Tylosky
Sara Tylosky, CEO of Farmacon, discusses AI-driven clinical development, the growing role of Latin America in global research, and the blurring line between pharmaceuticals and nutraceuticals.
▶
48:49 ODC Life Sciences CEO on Running Trials in Latin America
Daniel Zequeto, Founder and CEO of ODC Life Sciences, discusses clinical development and patient recruitment in Brazil and Latin America, and what sponsors need for trials there in rare diseases, hematology, oncology, nephrology and neurology, for bioaccess.
▶
50:04 China's Biotech Rise and Clinical Trials
Tim Scott, President and CEO of Biocom, shares observations from a biotech delegation to Shanghai, including how China's investigator-initiated trials work, trial-ready cohorts, licensing and what it means for U.S. competition, for the Making Medicine Podcast.
▶
23:48 Clinical Trials in India Explained: From Regulatory Strategy to Patient Enrollment
Dr. Deepa Arora, CEO of CLINEXEL, on why India has become a destination for global trials, comparing it with Europe on patient access, regulatory pathways, timelines and cost.
▶
19:56 Patient Population First: The Strategy Behind Country Decisions
pharmaphorum on choosing which countries a trial will run in, and why recruitment risk is locked in at that decision rather than when sites open.
▶
39:57 AAIC 2026 Findings for Familial Alzheimer's Families
Youngtimers reviews findings from AAIC 2026 and the DIAD Family Conference for familial Alzheimer's families, including results for tau drugs E2814 and diranersen, blood tests and prevention trials starting earlier.
▶
1:21:23 Clinical Trials and the Future of Cancer Care in Canada
A CAPT-ACTP 2026 conference panel discusses how clinical trials can help Canada prepare for personalised cancer treatments, from staffing and infrastructure to regulatory and reimbursement processes.
▶
17:28 Big Pharma Needs New Drugs. China Has Them
Bloomberg reporters Amber Tong and Robert Langreth explain why US drugmakers are increasingly licensing drugs discovered, tested and developed in Chinese labs, and what it means for US biotech, on Bloomberg's Big Take Asia.
▶
12:00 Tess Cameron, RA Capital, on China Biopharma Going Global
Tess Cameron, Managing Director at RA Capital, discusses how the firm views cross-border assets, clinical trial execution in China and global biotech dealmaking, in PharmCube's BIO & Beyond series.
▶
34:23 Unpacking the EU Biotech Act
Eline D'Joos, a life sciences associate in Crowell & Moring's Brussels office, discusses the EU Biotech Act, a legislative proposal on health biotechnology that aims to streamline clinical trials and boost biomanufacturing, for CITI Program.
▶
1:10:01 Expanding Access to Cell and Gene Therapies Across Africa
Speakers from Makerere University, Moi University and Benjamin Mkapa Hospital describe the regulatory, logistical and infrastructure challenges of establishing cell and gene therapy programmes in African countries, in an ASGCT webinar.
▶
7:41 Scott Gottlieb on China's Biotech Strategy
Former FDA Commissioner Dr. Scott Gottlieb discusses China's biotech strategy and how China is gaining ground on the U.S. in the biotech sector, on CNBC's Squawk Box.
▶
2:01 Improving Clinical Trials in the EU
EU Clinical Trials underwent a change in January 2022 as highlighted n this video from the European Medicines Agency that discusses the Clinical Trial Regulation and the new Clinical Trials Information System (also called CTIS).
▶
1:07:01 Early-Phase Oncology Trials in Australia and the USA
An Avance Clinical webinar on running early-phase oncology trials in Australia under the TGA Clinical Trial Notification scheme and R&D tax incentive, then moving to the USA for later-stage trials aligned with FDA requirements.
▶
35:09 UK Clinical Trials Regulations 2025 Are You Prepared 10 March 2026 (Webinar Recording)
A Fusion Pharma webinar on the new UK Clinical Trials Regulations in force from 28 April 2026, covering combined review, notifiable trials, modifications, safety reporting and consent.
▶
51:57 Comparing CTA and IND Submissions for Phase I Trials
Altasciences' Dr. Beatrice Setnik and colleagues compare Health Canada and EMA clinical trial applications with FDA IND submissions for first-in-human trials, including pre-submission meetings, required content and approval timelines.